Replimune (REPL) Common Equity (2018 - 2025)

Replimune has disclosed Common Equity across 8 years of filings, most recently posting $210.5 million for Q4 2025.

• Common Equity for Q4 2025 came in at $210.5 million, down 56.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $210.5 million (down 56.35% YoY), and the FY2025 annual result was $415.8 million, up 11.04% from the prior year.
• Common Equity came in at $210.5 million for Q4 2025 at Replimune, down from $263.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $595.3 million in Q4 2022 to a low of $210.5 million in Q4 2025.
• The 5-year median for Common Equity is $424.0 million (2023), against an average of $426.0 million.
• Across the five-year window, Common Equity soared 171.46% in 2021 and plunged 56.35% in 2025, its largest moves.
• Replimune's Common Equity stood at $437.5 million in 2021, then jumped by 36.08% to $595.3 million in 2022, then decreased by 29.19% to $421.5 million in 2023, then advanced by 14.43% to $482.4 million in 2024, then slumped by 56.35% to $210.5 million in 2025.
• The last three Common Equity figures came in at $210.5 million (Q4 2025), $263.3 million (Q3 2025), and $336.7 million (Q2 2025), per Business Quant data.